Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges.

Smith DW, Stoimenova D, Eid K, Barqawi A.

Prostate Cancer. 2012;2012:587139. doi: 10.1155/2012/587139. Epub 2012 Dec 31.

2.

Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy.

Barqawi AB, Krughoff KJ, Eid K.

Adv Urol. 2012;2012:862639. doi: 10.1155/2012/862639. Epub 2012 May 10.

4.

Evaluating localized prostate cancer and identifying candidates for focal therapy.

Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT.

Urology. 2008 Dec;72(6 Suppl):S12-24. doi: 10.1016/j.urology.2008.10.004.

PMID:
19095124
5.

Targeted focal therapy for prostate cancer: a review.

Hou AH, Sullivan KF, Crawford ED.

Curr Opin Urol. 2009 May;19(3):283-9. doi: 10.1097/MOU.0b013e32832a2c4a. Review.

PMID:
19357510
7.

Conventional treatments of localized prostate cancer.

Zerbib M, Zelefsky MJ, Higano CS, Carroll PR.

Urology. 2008 Dec;72(6 Suppl):S25-35. doi: 10.1016/j.urology.2008.10.005.

PMID:
19095125
8.

[Adenocarcinoma of the prostate].

Dvorácek J.

Cas Lek Cesk. 1998 Aug 31;137(17):515-21. Review. Czech.

PMID:
9787503
9.

Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.

Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A.

BJU Int. 2012 Mar;109 Suppl 2:1-7. doi: 10.1111/j.1464-410X.2011.10870.x.

11.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
12.

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.

Wilt TJ.

Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.

PMID:
11828353
13.

Population screening for prostate cancer and emerging concepts for young men.

Moul JW.

Clin Prostate Cancer. 2003 Sep;2(2):87-97. Review.

PMID:
15040869
14.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

15.

Active surveillance for localized prostate cancer--current practices and recommendations.

Wu JN, Dall'Era MA.

ScientificWorldJournal. 2010 Dec 14;10:2352-61. doi: 10.1100/tsw.2010.227.

16.

Active surveillance for prostate cancer: progress and promise.

Cooperberg MR, Carroll PR, Klotz L.

J Clin Oncol. 2011 Sep 20;29(27):3669-76. doi: 10.1200/JCO.2011.34.9738. Epub 2011 Aug 8. Review.

17.

Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer.

Nomura T, Mimata H.

Adv Urol. 2012;2012:391437. doi: 10.1155/2012/391437. Epub 2012 Apr 24.

18.

Active surveillance versus radical treatment for favorable-risk localized prostate cancer.

Klotz L.

Curr Treat Options Oncol. 2006 Sep;7(5):355-62. Review.

PMID:
16904052
19.

Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?

Radomski L, Gani J, Trottier G, Finelli A.

Can J Urol. 2012 Jun;19(3):6287-92.

PMID:
22704315
20.

[Prostate cancer treatments in Belgium].

Kaitouni MI, Roumeguère T.

Rev Med Brux. 2009 Sep;30(4):270-8. French.

PMID:
19899373

Supplemental Content

Support Center